Faktor-faktor Yang Mempengaruhi Kejadian Anemia Pada Pemakaian Zidovudin Pasien Hiv/aids (Studi Kasus Di Rsup Dr. Kariadi Semarang)

Background: The administration of Zidovudine (ZDV) has an important role in decreasing the number of mortality on HIV/AIDS patients. Nevertheless, Zidovudine is known to make a side effect of anaemia. The incidence of anaemia can be influenced by several factors, e.g. age, sex, duration of therapy, CD4 count, and ALT count.Aims: This research aims to determine factors influencing incidence of anaemia on HIV/AIDS patients with Zidovudine treatment in Dr. Kariadi General Hospital Semarang and see the correlation between those determinant factors to the incidence of anaemia.Methods: This research is an analytic observational with cohort-retrospective method used. There were 70 HIV/AIDS patients with Zidovudine, divided into two groups: 35 patients belonged to case group, while the other 35 patients belonged to control group. The data was taken from medical records and analyzed by Chi-square and Fischer test.Results: Age did not have any correlation to incidence of anaemia (p=0.075). Sex was a contributing factor to incidence of anaemia (p=0.027) in which female patients were more susceptible to anaemia. Duration of therapy was a contributing factor to incidence of anaemia (p=0.000) particularly patients with less than 12 months of therapy. CD4 count did not have any correlation to incidence of anaemia (p=0.055). ALT count did not have any correlation to incidence of anaemia (p=1.000).Conclusion: The administration of Zidovudine corresponds to the incidence of anaemia with sex and duration of therapy as the influencing factors on HIV/AIDS patients in Dr. Kariadi General Hospital Semarang

Taux de perte en vaccins et efficience du Programme élargi de vaccination : où en est-on dans les districts sanitaires africains ?.

Développement économique; Projets; Évaluation; Vaccination; Afrique;

A Sensor-Based Methodology to Differentiate Pure and Mixed White Tequilas Based on Fused Infrared Spectra and Multivariate Data Treatment

[Abstract]: Mexican Tequila is one of the most demanded import spirits in Europe. Its fast-raising worldwide request makes counterfeiting a profitable activity affecting both consumers and legal distillers. In this paper, a sensor-based methodology based on a combination of infrared measurements (IR) and multivariate data analysis (MVA) is presented. The case study is about differentiating two categories of white Tequila: pure Tequila (or ‘100% agave’) and mixed Tequila (or simply, Tequila). The IR spectra were treated and fused with a low-level approach. Exploratory data analysis was performed using PCA and partial least squares (PLS), whilst the authentication analyses were carried out with PLS-discriminant analysis (DA) and soft independent modeling for class analogy (SIMCA) models. Results demonstrated that data fusion of IR spectra enhanced the outcomes of the authentication models capable of differentiating pure from mixed Tequilas. In fact, PLS-DA presented the best results which correctly classified all fifteen commercial validation samples. The methodology thus presented is fast, cheap, and of simple application in the Tequila industry.Universidad Nacional Autónoma de México; PIAPI 2042Universidad Nacional Autónoma de México; PAPIIT IT20091

Examining the efficacy of a self-administered report form in missing person investigations

PurposeThe success of missing person investigations often centres on the quality of information obtained in the early stages. Reliable information can not only inform the search but might also become vital evidence if the case broadens into a criminal investigation relating to a sexual offence, abduction, or even murder. In addition to eliciting high quality information, police officers must consider that those close to the missing person are likely going through a very difficult and stressful time. Across two studies, we developed and tested a self-administered form (SAI-MISSING) designed to obtain reliable information that would meaningfully inform a missing person investigation, as well as providing a means for family and friends to be actively involved.MethodsIn Experiment 1, 65 participants were tested individually and asked to provide a description of a person they knew well but had not seen for 24 hours. In the second study, 64 participants were tested in pairs, but immediately separated into different rooms and instructed to imagine that the person they came with has gone missing. In both studies participants completed either the SAI-MISSING tool, or a self-administered control form.ResultsIn Experiment 1 we found that the SAI-MISSING tool elicited significantly more information regarding physical descriptions and descriptions of clothing and personal effects, than the comparison control form. In Experiment 2 we replicated this finding, and further showed that the SAI-MISSING tool produced higher accuracy rates than the control form.ConclusionsGiven our positive findings, potential applications of the tool are discussed

Baseline characteristics of patients in the reduction of events with darbepoetin alfa in heart failure trial (RED-HF)

<p>Aims: This report describes the baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF) which is testing the hypothesis that anaemia correction with darbepoetin alfa will reduce the composite endpoint of death from any cause or hospital admission for worsening heart failure, and improve other outcomes.</p> <p>Methods and results: Key demographic, clinical, and laboratory findings, along with baseline treatment, are reported and compared with those of patients in other recent clinical trials in heart failure. Compared with other recent trials, RED-HF enrolled more elderly [mean age 70 (SD 11.4) years], female (41%), and black (9%) patients. RED-HF patients more often had diabetes (46%) and renal impairment (72% had an estimated glomerular filtration rate <60 mL/min/1.73 m2). Patients in RED-HF had heart failure of longer duration [5.3 (5.4) years], worse NYHA class (35% II, 63% III, and 2% IV), and more signs of congestion. Mean EF was 30% (6.8%). RED-HF patients were well treated at randomization, and pharmacological therapy at baseline was broadly similar to that of other recent trials, taking account of study-specific inclusion/exclusion criteria. Median (interquartile range) haemoglobin at baseline was 112 (106–117) g/L.</p> <p>Conclusion: The anaemic patients enrolled in RED-HF were older, moderately to markedly symptomatic, and had extensive co-morbidity.</p&gt

Why Are Outcomes Different for Registry Patients Enrolled Prospectively and Retrospectively? Insights from the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF).

Background: Retrospective and prospective observational studies are designed to reflect real-world evidence on clinical practice, but can yield conflicting results. The GARFIELD-AF Registry includes both methods of enrolment and allows analysis of differences in patient characteristics and outcomes that may result. Methods and Results: Patients with atrial fibrillation (AF) and ≥1 risk factor for stroke at diagnosis of AF were recruited either retrospectively (n = 5069) or prospectively (n = 5501) from 19 countries and then followed prospectively. The retrospectively enrolled cohort comprised patients with established AF (for a least 6, and up to 24 months before enrolment), who were identified retrospectively (and baseline and partial follow-up data were collected from the emedical records) and then followed prospectively between 0-18 months (such that the total time of follow-up was 24 months; data collection Dec-2009 and Oct-2010). In the prospectively enrolled cohort, patients with newly diagnosed AF (≤6 weeks after diagnosis) were recruited between Mar-2010 and Oct-2011 and were followed for 24 months after enrolment. Differences between the cohorts were observed in clinical characteristics, including type of AF, stroke prevention strategies, and event rates. More patients in the retrospectively identified cohort received vitamin K antagonists (62.1% vs. 53.2%) and fewer received non-vitamin K oral anticoagulants (1.8% vs . 4.2%). All-cause mortality rates per 100 person-years during the prospective follow-up (starting the first study visit up to 1 year) were significantly lower in the retrospective than prospectively identified cohort (3.04 [95% CI 2.51 to 3.67] vs . 4.05 [95% CI 3.53 to 4.63]; p = 0.016). Conclusions: Interpretations of data from registries that aim to evaluate the characteristics and outcomes of patients with AF must take account of differences in registry design and the impact of recall bias and survivorship bias that is incurred with retrospective enrolment. Clinical Trial Registration: - URL: http://www.clinicaltrials.gov . Unique identifier for GARFIELD-AF (NCT01090362)

Erratum to: 36th International Symposium on Intensive Care and Emergency Medicine

[This corrects the article DOI: 10.1186/s13054-016-1208-6.]

Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation.

OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was developed, using stepwise regression, for all and then applied to lower risk patients. C-statistics were compared with CHA2DS2-VASc using 30-fold cross-validation to control for overfitting. External validation was undertaken in an independent dataset, Outcome Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). PARTICIPANTS: Data from 39 898 patients enrolled in the prospective GARFIELD-AF registry provided the basis for deriving and validating an integrated risk tool to predict stroke risk, mortality and bleeding risk. RESULTS: The discriminatory value of the GARFIELD-AF risk model was superior to CHA2DS2-VASc for patients with or without anticoagulation. C-statistics (95% CI) for all-cause mortality, ischaemic stroke/systemic embolism and haemorrhagic stroke/major bleeding (treated patients) were: 0.77 (0.76 to 0.78), 0.69 (0.67 to 0.71) and 0.66 (0.62 to 0.69), respectively, for the GARFIELD-AF risk models, and 0.66 (0.64-0.67), 0.64 (0.61-0.66) and 0.64 (0.61-0.68), respectively, for CHA2DS2-VASc (or HAS-BLED for bleeding). In very low to low risk patients (CHA2DS2-VASc 0 or 1 (men) and 1 or 2 (women)), the CHA2DS2-VASc and HAS-BLED (for bleeding) scores offered weak discriminatory value for mortality, stroke/systemic embolism and major bleeding. C-statistics for the GARFIELD-AF risk tool were 0.69 (0.64 to 0.75), 0.65 (0.56 to 0.73) and 0.60 (0.47 to 0.73) for each end point, respectively, versus 0.50 (0.45 to 0.55), 0.59 (0.50 to 0.67) and 0.55 (0.53 to 0.56) for CHA2DS2-VASc (or HAS-BLED for bleeding). Upon validation in the ORBIT-AF population, C-statistics showed that the GARFIELD-AF risk tool was effective for predicting 1-year all-cause mortality using the full and simplified model for all-cause mortality: C-statistics 0.75 (0.73 to 0.77) and 0.75 (0.73 to 0.77), respectively, and for predicting for any stroke or systemic embolism over 1 year, C-statistics 0.68 (0.62 to 0.74). CONCLUSIONS: Performance of the GARFIELD-AF risk tool was superior to CHA2DS2-VASc in predicting stroke and mortality and superior to HAS-BLED for bleeding, overall and in lower risk patients. The GARFIELD-AF tool has the potential for incorporation in routine electronic systems, and for the first time, permits simultaneous evaluation of ischaemic stroke, mortality and bleeding risks. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier for GARFIELD-AF (NCT01090362) and for ORBIT-AF (NCT01165710)